[1]王欣,谭详敏,王梅竹,等.中药砷剂治疗BCR-ABL阳性慢性髓系白血病研究进展[J].中国中医药信息杂志,2020,27(6):136-140.[doi:10.3969/j.issn.1005-5304.201905205]
 WANG Xin,TAN Xiangmin,WANG Meizhu,et al.Research Progress inTCM Arsenic for Treatment of BCR-ABL Positive Chronic Myeloid Leukemia[J].zhongguo zhongyiyao xinxi zazhi,2020,27(6):136-140.[doi:10.3969/j.issn.1005-5304.201905205]
点击复制

中药砷剂治疗BCR-ABL阳性慢性髓系白血病研究进展

参考文献/References:

[1] CHEREDA B, MELO J V. Natural course and biology of CML[J]. Annals of Hematology,2015,94(Suppl2):S107-121.

[2] COQUERET O. Linking cyclins to transcriptional control[J]. Gene,2002,299(1/2):35-55.

[3] 王凡平,张婧婧,房丽敏,等.三氧化二砷对K562细胞增殖作用的影响和机制[J].中国实验血液学杂志,2016,24(6):1725-1729.

[4] 王愿,杨洁,李杰,等.三氧化二砷对K562细胞增殖抑制作用及其机制研究[J].中国实验血液学杂志,2017,25(1):90-93.

[5] 陈智超,大西一功,游泳,等.三氧化二砷诱导慢性髓系白血病细胞G2/M周期停滞及其机理[J].华中科技大学学报(医学版),2003,32(6):610-612,615.

[6] MASUMOTO J, TANIGUCHI S, AYUKAWA K, et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells[J]. The Journal of Biological Chemistry, 1999,274(48):33835-33838.

[7] LI H, WANG Y, XU W, et al. Arsenic trioxide inhibits DNA methyltransferase and restores TMS1 gene expression in K562 cells[J]. Acta Haematologica,2015,133(1):18-25.

[8] YOSHIDA K, MIKI Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage[J]. Cancer Science, 2010,101(4):831-835.

[9] 王颖超.三氧化二砷对慢粒细胞系K562的促凋亡作用及其机理研究[D].长沙:中南大学,2003.

[10] WANGD H, WEI H L, ZHAO H S, et al. Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway[J]. Pharmacological Research, 2005,52(5):376-385.

[11] XIA Y, FANG H, ZHANG J, et al. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide[J]. Experimental Biology and Medicine (Maywood, NJ),2013,238(8):932-942.

[12] XU W, WEI W, YU Q, et al. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abldependent mechanisms[J]. Molecular Medicine Reports, 2014,10(3):1519-1524.

[13] LI N, GUAN X, LI F, et al. Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line[J]. Peer J,2015,3:e962.

[14] ZHENG K, HE Z, KITAZATO K, et al. Selective autophagy regulates cell cycle in cancer therapy[J]. Theranostics,2019,9(1):104-125.

[15] CHENG J, WEI H L, CHEN J, et al. Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy[J]. Toxicology Mechanisms and Methods,2012,22(7):512-519.

[16] 刘金花.三氧化二砷对Bcr-Abl耐药突变细胞株抑制作用及其作用机制[D].长春:东北农业大学,2010.

[17] GOUSSETIS D J, GOUNARIS E, WU E J, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide[J]. Blood,2012,120(17):3555-3562.

[18] 陆道培,江滨,邱镜滢.三硫化二砷治疗急性早幼粒细胞白血病首例报告[J].北京医科大学学报,2000,32(3):256-257.

[19] 林梅.雌黄纳米粒的研制及其体外抗肿瘤作用和分子机制的实验研究[D].南京:东南大学,2006.

[20] 林梅,张东生,李华,等.雌黄纳米粒对K562细胞的体外治疗作用及其机制[J].纳米技术与精密工程,2008,6(1):14-19.

[21] 林梅,张东生.纳米雌黄对K562细胞端粒酶活性的影响[J].实用临床医药杂志,2007,11(6):5-7.

[22] LIN M, WANG Z, ZHANG D. Preparation of orpiment nanoparticles and their cytotoxic effect on cultured leukemia K562 cells[J]. Journal of Nanoscience and Nanotechnology,2007,7(2):490-496.

[23] SHIN S, SUNG B J, CHO Y S, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7[J]. Biochemistry,2001,40(4):1117-1123.

[24] FEI J, LI Y, ZHU X, et al. miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML)[J]. PloS One, 2012,7(3):e32834.

[25] GONG J, ZHENG S, ZHANG L, et al. Induction of K562 Cell Apoptosis by As4S4 via down-regulating miR181[J]. Medical Science Monitor:Iternational Medical Journal of Experimental and Clinical Research,2017,23:144-150.

[26] WANG L, XING H, ZHANG X, et al. The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation[J]. Journal of Hematology & Oncology,2014, 7:61.

[27] 李静,刘陕西,张梅,等.雄黄对K562细胞端粒酶活性和凋亡的作用[J].第四军医大学学报,2003,24(17):1581-1583.

[28] 李俊娥,孙关林,吴英理,等.As2S2诱导K562细胞凋亡的分子机制初步研究[J].中华肿瘤杂志,2003,25(3):16-20.

[29] 董合玲,徐晓阳.泛素-蛋白酶体途径的组成及其生物功能[J].南京体育学院学报:自然科学版,2011,10(3):35-37.

[30] MAO J H, SUN X Y, LIU J X, et al. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia[J]. Proceedings of the National Academy of Sciences of the United States of America,2010,107(50):21683- 21688.

[31] 刘艳,王洋,史丹,等.肿瘤细胞的自噬和窖蛋白-1[J].生物工程学报,2012,28(8):912-917.

[32] SHATA M, LISCOVITCH M. Caveolin-1:a tumor-promoting role in human cancer[J]. International Journal of Radiation Biology, 2008,84(3):177-189.

[33] SHI D, LIU Y, XI R, et al. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells[J]. International Journal of Nanomedicine,2016,11:5823- 5835.

[34] CHEN P, YAN L, LENG F, et al. Bioleaching of realgar by Acidithiobacillusferrooxidans using ferrous iron and elemental sulfur as the sole and mixed energy sources[J]. Bioresource Technology,2011,102(3):3260-3267.

[35] WANG X, ZHANG X, XU Z, et al. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution[J]. Biological & Pharmaceutical Bulletin,2013,36(4):641-648.

[36] SONG P, HAI Y, WANG X, et al. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells[J]. Archives of Pharmacal Research,2018,41(4):467-480.

[37] WANG X, CHEN B, ZHAO L, et al. Autophagy enhanced antitumor effect in K562 and K562/ADM cells using realgar transforming solution[J]. Biomedicine & Pharmacotherapy & Biomedecine & Pharmacotherapie,2018,98:252-264.

[38] ZHANG X, XIE Q J, WANG X, et al. Biological extraction of realgar by Acidithiobacillusferrooxidans and its in vitro and in vivo antitumor activities[J]. Pharmaceutical Biology,2010,48(1):40- 47.

[39] XIE Q J, CAO X L, BAI L, et al. Anti-tumor effects and apoptosis induction by Realgar bioleaching solution in Sarcoma-180 cells in vitro and transplanted tumors in mice in vivo[J]. Asian Pacific Journal of Cancer Prevention,2014,15(6):2883-2888.

[40] SONG P, CHEN P, WANG D, et al. Realgar transforming solution displays anticancer potential against human hepatocellular carcinoma HepG2 cells by inducing ROS[J]. International Journal of Oncology,2017,50(2):660-670.

[41] 张罩沐,许长江,张予.多药抗药性产生机理[J].中国药理学通报, 1994,7(4):246-249.

[42] LEUNG J, PANG A, YUEN W H, et al. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells[J]. Blood,2007,109(2):740-746.

备注/Memo

基金项目:国家自然科学基金(81403145、81560715);国家科技重大专项-重大新药创制(2015ZX09501-004-008);中央高校基本科研业务费专项资金(lzujbky-2018-136、lzujbky-2017-206)

更新日期/Last Update:

2020-05-14